Robertson S - Search Results

1

Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist.

Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry T, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MV, Robertson S, Weiner AL, Sallee VL. Hellberg MR, et al. Among authors: robertson s. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S13-33. doi: 10.1016/s0039-6257(02)00293-x. Surv Ophthalmol. 2002. PMID: 12204698

2

Response to travoprost in black and nonblack patients with open-angle glaucoma or ocular hypertension.

Netland PA, Robertson SM, Sullivan EK, Silver L, Bergamini MV, Krueger S, Weiner AL, Davis AA; Travoprost Study Groups. Netland PA, et al. Among authors: robertson sm. Adv Ther. 2003 May-Jun;20(3):149-63. doi: 10.1007/BF02850202. Adv Ther. 2003. PMID: 12956257 Clinical Trial.

3

Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension.

Schuman JS, Katz GJ, Lewis RA, Henry JC, Mallick S, Wells DT, Sullivan EK, Landry TA, Bergamini MV, Robertson SM. Schuman JS, et al. Among authors: robertson sm. Am J Ophthalmol. 2005 Aug;140(2):242-50. doi: 10.1016/j.ajo.2005.02.058. Am J Ophthalmol. 2005. PMID: 16086946 Clinical Trial.

4

Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure.

Dubiner HB, Sircy MD, Landry T, Bergamini MV, Silver LH, Darell Turner F, Robertson S, Andrew RM, Weiner A, Przydryga J. Dubiner HB, et al. Among authors: robertson s. Clin Ther. 2004 Jan;26(1):84-91. doi: 10.1016/s0149-2918(04)90008-2. Clin Ther. 2004. PMID: 14996520 Clinical Trial.

5

Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension.

Netland PA, Landry T, Sullivan EK, Andrew R, Silver L, Weiner A, Mallick S, Dickerson J, Bergamini MV, Robertson SM, Davis AA; Travoprost Study Group. Netland PA, et al. Among authors: robertson sm. Am J Ophthalmol. 2001 Oct;132(4):472-84. doi: 10.1016/s0002-9394(01)01177-1. Am J Ophthalmol. 2001. PMID: 11589866 Clinical Trial.

6

Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.

Slakter JS, Bochow TW, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, Robertson SM, Slakter JS, Sullins G, Zilliox P; Anecortave Acetate Clinical Study Group. Slakter JS, et al. Among authors: robertson sm. Ophthalmology. 2006 Jan;113(1):3-13. doi: 10.1016/j.ophtha.2005.10.019. Epub 2005 Dec 20. Ophthalmology. 2006. PMID: 16368146 Clinical Trial.

7

Preclinical and clinical antiallergic effect of olopatadine 0.2% solution 24 hours after topical ocular administration.

Vogelson CT, Abelson MB, Pasquine T, Stephens DM, Gamache DA, Gross RD, Robertson SM, Yanni JM. Vogelson CT, et al. Allergy Asthma Proc. 2004 Jan-Feb;25(1):69-75. Allergy Asthma Proc. 2004. PMID: 15055565 Clinical Trial.

8

Clinical efficacy of olopatadine hydrochloride ophthalmic solution 0.2% compared with placebo in patients with allergic conjunctivitis or rhinoconjunctivitis: a randomized, double-masked environmental study.

Abelson MB, Gomes PJ, Vogelson CT, Pasquine TA, Gross RD, Turner FD, Wells DT, Bergamini MV, Robertson SM. Abelson MB, et al. Clin Ther. 2004 Aug;26(8):1237-48. doi: 10.1016/s0149-2918(04)80065-1. Clin Ther. 2004. PMID: 15476905 Clinical Trial.

9

Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy.

D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EK, Yannuzzi L, Zilliox P; Anecortave Acetate Clinical Study Group. D'Amico DJ, et al. Among authors: robertson sm. Retina. 2003 Feb;23(1):14-23. doi: 10.1097/00006982-200302000-00003. Retina. 2003. PMID: 12652226 Clinical Trial.

10

Regulatory T cells promote decidual vascular remodeling and modulate uterine NK cells in pregnant mice.

Hosking SL, Moldenhauer LM, Tran HM, Chan HY, Groome HM, Lovell EA, Green ES, O'Hara SE, Roberts CT, Foyle KL, Davidge ST, Robertson SA, Care AS. Hosking SL, et al. Among authors: robertson sa. JCI Insight. 2024 Dec 10:e169836. doi: 10.1172/jci.insight.169836. Online ahead of print. JCI Insight. 2024. PMID: 39656539 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,886 results

Search Page

Filters